ArticleJournal of pharmaceutical policy and practice2025
Validity and reliability of Medication Adherence Report Scale (MARS-5) in a Southeastern European population.
Article in Journal of pharmaceutical policy and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- mHealth for chronic disease management: effects on adherence in Ghanaian patients with diabetes and hypertension.Journal of global health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Medication adherence improves health outcomes and overall well-being. Questionnaires and reporting scales remain the most accessible and cost-effective assessment tools for adherence; however, they must demonstrate validity, reliability, and sensitivity to change. The aim of this study is to assess the validity and reliability of the Medication Adherence Report Scale (MARS-5) in the adult population of Albania and to examine the correlations between the adjusted summary scores of MARS-5 and the sociodemographic and health status characteristics of the study population. Methods: A cross-sectional study was conducted in Albania during November-December 2024, including a sample of 256 individuals ≥18 years with hypertension, diabetes, or both conditions. The Albanian version of MARS-5 translated, according to guidelines, was administered twice (over two weeks) in-person to patients visiting primary health care settings (≈56% females; response: ≈85%). Participants also reported on sociodemographic factors and health status characteristics. Cronbach's alpha was used to measure internal consistency and Pearson's correlation coefficient for the assessment of test-retest reliability. Results: Cronbach's alpha was 0.89 for the test and 0.91 for the retest. Test-retest reliability was high (r = 0.95, Conclusion: MARS-5 is a valid and reliable tool for assessing medication adherence in the adult population of Albania.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.